Cue Biopharma, Inc. (NASDAQ:CUE) Q4 2022 Earnings Call Transcript
Operator: Greetings, and welcome to the Cue Biopharma Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, this conference is being recorded.
Cue Biopharma Inc. (CUE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Slate Path Capital David Greenspan | 2,402,455 | $8,576,764 | 0.4% | |
| 2. | Prosight Capital Lawrence Hawkins | 1,151,855 | $4,112,122 | -38% | 1.94% |
| 3. | SilverArc Capital Devesh Gandhi | 306,278 | $1,093,412 | 0.45% | |
| 4. | Carlson Capital Clint Carlson | 254,036 | $906,909 | -31% | 0.08% |
| 5. | P.A.W. CAPITAL PARTNERS Peter A. Wright | 150,000 | $535,500 | -17% | 1.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.75 | 28,000 | Director | 28,000 | 2022-05-27 | Filing | |
| $3.34 | 55,000 | Director | 940,000 | 2022-05-24 | Filing | |
| $3.52 | 150,000 | Director | 885,000 | 2022-05-23 | Filing | |
| $4.76 | 735,000 | Director | 735,000 | 2022-03-31 | Filing | |
| $14.72 | 3,400 | Officer, Director | 55,377 | 2021-09-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.28 | 9,325 | Director | 357 | 2023-03-23 | Filing | |
| $18.02 | 1,361 | Director | 0 | 2021-11-16 | Filing | |
| $17.92 | 18,815 | Director | 0 | 2021-11-15 | Filing | |
| $18.05 | 8,000 | Officer | 94,038 | 2021-11-15 | Filing | |
| $15.07 | 20,000 | Officer | 94,038 | 2021-11-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 1,653,596 | $5,903,338 | 0% | |
| 2. | 755,028 | $2,695,450 | 0.57% | |
| 3. | 664,426 | $2,372,000 | 0% | |
| 4. | 545,624 | $1,947,824 | 0% | |
| 5. | 478,500 | $1,708,245 | 0.13% |
News See All
Hedge Fund and Insider Trading News: George Soros, Alan Howard, Ken Griffin, Bill Ackman, Elliott Management, Bridgewater Associates, Angelo Gordon & Co., Averill Partners, Cue Biopharma Inc (CUE), Noble Corporation (NE), and More
The world's largest hedge fund is sounding the alarm over a possible return to 1970s-style "stagflation," as the Federal Reserve moves to tame sky-high inflation.
5 Pharmaceutical Stocks to Buy According to Lawrence Hawkins' Prosight Capital
In this article, we discuss 5 pharmaceutical stocks to buy according to Lawrence Hawkins' Prosight Capital.
Is CUE A Good Stock To Buy Now?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Keep Buying Cue Biopharma, Inc. (CUE)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Hedge Funds Have Never Been This Bullish On Cue Biopharma, Inc. (CUE)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Have Never Been This Bullish On Cue Biopharma, Inc. (CUE)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Billionaire Hedge Funds
